24
Participants
Start Date
May 19, 2021
Primary Completion Date
May 20, 2026
Study Completion Date
May 20, 2031
177Lu-DOTATATE
A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
RECRUITING
Rigshospitalet, Copenhagen
RECRUITING
Vilnius University Hospital, Vilnius
RECRUITING
Princess Maxima Center for Pediatric Oncology, Utrecht
RECRUITING
Oslo University Hospital, Rikshospitalet, Oslo
RECRUITING
Karolinska University Hospital, Stockholm
Collaborators (2)
Advanced Accelerator Applications
INDUSTRY
Novartis
INDUSTRY
Jakob Stenman
OTHER